Novel GLP-1/GIP dual receptor agonist alleviates neonatal hypoxic-ischemic encephalopathy by inhibiting TLR2/NF-B/NLRP3 mediated-neuroinflammation
Providers could consider prescribing oral or subcutaneous semaglutide for approved indications if appropriate, since there was lack of evidence to support significant risk of cholelithiasis seen in one meta-analysis
Never share pens or needles with others, and never reuse needles
If you sign up through one of them we may earn a commission at no extra cost to you
Notably, it is a non-peptide, once-daily pill that can be taken without regard to food or water, marking an incremental but meaningful shift for a class long defined by injectables and more restrictive dosing requirements
Subsequently, multiple large outcome trials of SGLT2is have demonstrated a reduction in all-cause mortality and hospitalisation for heart failure in patients with HFrEF [20] and HFpEF [21], irrespective of diabetes status